Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Revolution Medicines (Nasdaq: RVMD) said CEO Mark A. Goldsmith, M.D., Ph.D., will take part in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 9:50 a.m. ET.
According to the company, a live webcast will be available and a replay will remain on the company website for at least 14 days.
Details
News Market Reaction – RVMD
On Feb 25, the first trading day after this news, RVMD closed 1.52% below the previous close.
Data tracked by StockTitan Argus for the Feb 25 session.
Key Figures
- Conference edition
- 46th Annual
- TD Cowen 46th Annual Health Care Conference
- Conference date
- March 3
- Date of TD Cowen conference fireside chat
- Start time
- 9:50 a.m. ET
- Scheduled time for the TD Cowen conference fireside chat
- Webcast replay window
- 14 days
- Replay available on company website after live webcast
Historical Context
-
Announcement of timing for Q4 and full-year 2025 results webcast.
-
Fireside chat at Guggenheim Emerging Outlook: Biotech Summit 2026.
-
First patient dosed in trial of RMC-5127, a RAS(ON) G12V inhibitor.
-
FDA Breakthrough Therapy Designation for zoldonrasib in KRAS G12D NSCLC.
-
J.P. Morgan Healthcare Conference presentation and webcast replay details.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
oncology medical
webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will participate in a fireside chat as part of the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3 at 9:50 a.m. ET.
To listen to a live webcast of this event, or access an archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcast, a replay will be available on the company’s website for at least 14 days.
About Revolution Medicines, Inc.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn.
Revolution Medicines Media & Investor Contact:
media@revmed.com
investors@revmed.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.